Investor Presentaiton
Strong Organic Growth in FY 2020 despite COVID-19
disruptions
19.3% organic growth in FY 2020
* eurofins
Strong organic growth compared to peers & three large in vitro diagnostic device (IVD) suppliers
Peers FY 2020 Organic Growth¹
25%
2
45%
19.3%
Prominent IVD actors FY 2020 Organic Growth*
40.6%
20%
40%
15%
35%
10%
30%
25%
2
5%
19.3%
20%
0%
15%
-5%
14.0%
9.5%
10%
-10%
-6.0%
-6.8%
-6.5%
5%
-15%
Eurofins
-11.8%
Applus
0%
Bureau
Veritas
Intertek
SGS
Eurofins
Abbott
(diagnostics)
Danaher
Roche
(diagnostics)
1 Based on public information, using each of the respective companies' Alternative Performance Measures (APM) definitions
2 Organic revenue growth including COVID-19 related clinical testing and reagent revenues and not corrected for the EUR 62m estimated missing revenues from the cyber-attack of 2 June 2019 as disclosed in Annual Report 2020
19View entire presentation